Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
M. J. van den Bent, C. M. S. Tesileanu, W. Wick, M. Sanson +37 more

